Mektovi (binimetinib) vs Braftovi (encorafenib)
Mektovi (binimetinib) vs Braftovi (encorafenib)
Mektovi (binimetinib) and Braftovi (encorafenib) are both targeted therapies used in the treatment of melanoma with a specific mutation known as BRAF V600E or V600K. Mektovi is a MEK inhibitor that works by interrupting the MEK pathway, which is part of a signaling chain that includes BRAF and is often overactive in melanoma, while Braftovi is a BRAF inhibitor that directly targets the mutated BRAF protein to prevent it from signaling cancer cell growth. The choice between Mektovi and Braftovi typically depends on the specific clinical scenario, including the presence of the BRAF mutation, the patient's overall health, and whether the drugs are being used in combination with other therapies, as they are often prescribed together to enhance treatment effectiveness. It is essential for patients to consult with their healthcare provider to determine the most appropriate treatment option for their individual condition.
Difference between Mektovi and Braftovi
| Metric | Mektovi (binimetinib) | Braftovi (encorafenib) |
|---|---|---|
| Generic name | Binimetinib | Encorafenib |
| Indications | Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test, in combination with encorafenib | Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test, in combination with binimetinib |
| Mechanism of action | MEK inhibitor (mitogen-activated protein kinase/extracellular signal-regulated kinase) | BRAF inhibitor |
| Brand names | Mektovi | Braftovi |
| Administrative route | Oral | Oral |
| Side effects | Fatigue, nausea, diarrhea, vomiting, abdominal pain, and rashes | Fatigue, nausea, diarrhea, vomiting, abdominal pain, and rashes |
| Contraindications | Hypersensitivity to binimetinib or any of the excipients | Hypersensitivity to encorafenib or any of the excipients |
| Drug class | Antineoplastic agent | Antineoplastic agent |
| Manufacturer | Array BioPharma Inc. (a subsidiary of Pfizer) | Pfizer Inc. |
Efficacy
Mektovi (binimetinib) and Braftovi (encorafenib) in the Treatment of Skin Cancer
Mektovi (binimetinib) and Braftovi (encorafenib) are targeted therapies approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Melanoma is the most serious type of skin cancer, and the presence of these specific mutations can drive the growth of cancer cells. The combination of Mektovi and Braftovi has been shown to inhibit these mutations, thereby impeding the progression of the disease.
The efficacy of Mektovi and Braftovi was primarily demonstrated in a Phase III clinical trial known as the COLUMBUS trial. This study compared the combination of binimetinib and encorafenib to encorafenib alone and to vemurafenib, another BRAF inhibitor. The results showed that the combination of Mektovi and Braftovi significantly improved progression-free survival (PFS) in patients with BRAF V600E or V600K mutation-positive melanoma. Specifically, the median PFS for patients treated with the combination was substantially longer compared to vemurafenib, a previously established treatment for this condition.
Additionally, the combination therapy not only improved PFS but also demonstrated an improvement in overall survival (OS) compared to vemurafenib. The median OS for patients receiving Mektovi and Braftovi was significantly extended, indicating that this combination could potentially offer a survival benefit to patients with BRAF-mutant melanoma. The objective response rate (ORR), which measures the percentage of patients with a partial or complete reduction of the tumor, was also higher in the combination therapy group.
It is important to note that while Mektovi and Braftovi have shown efficacy in the treatment of BRAF V600E or V600K mutation-positive melanoma, they are not suitable for all patients with skin cancer. The presence of the specific BRAF mutation is a prerequisite for the use of these drugs, and their administration should be guided by an FDA-approved test to confirm the mutation status. Additionally, the safety and efficacy of Mektovi and Braftovi in other forms of skin cancer have not been established. As with all medications, potential side effects and contraindications should be discussed with a healthcare provider before starting treatment.
Regulatory Agency Approvals
Mektovi
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Braftovi
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Mektovi or Braftovi today
If Mektovi or Braftovi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us